In this regard, previous studies conducted by Gomez-Ospina et al., using the CRISPR/Cas9 system to edit HSPCs at the CCR5 locus, demonstrated that ex vivo CRISPR/Cas9-based GT could improve bone lesions in MPS I mice upon transplantation [39]. This evidence concerns the gene CCR5 and Scheie syndrome.